Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 441: All of the following are true regarding muscarinic actions except:

A. Miosis
B. Detrusor muscle contraction
C. Dicyclomine is an antimuscarinic drug used for smooth muscle relaxation
D. Cardiac muscarinic receptors are predominantly M3 type (Correct Answer)

Explanation: ### Explanation The correct answer is **D**, as cardiac muscarinic receptors are predominantly **M2 type**, not M3. **1. Why Option D is the Correct Answer (The False Statement):** Muscarinic receptors are classified into five subtypes (M1–M5). While M3 receptors are widely distributed in smooth muscles and glands, the heart is the primary site for **M2 receptors**. These are G-protein coupled receptors (Gi type) that decrease cAMP, leading to negative chronotropic (rate), dromotropic (conduction), and inotropic (contractility) effects. **2. Analysis of Other Options:** * **Option A (Miosis):** True. Muscarinic stimulation (M3) of the circular muscles (sphincter pupillae) of the iris causes contraction, leading to pupillary constriction (miosis). * **Option B (Detrusor contraction):** True. The bladder contains M3 receptors. Their activation causes the detrusor muscle to contract and the trigone/sphincter to relax, facilitating micturition. * **Option C (Dicyclomine):** True. Dicyclomine is a tertiary amine antimuscarinic agent. It acts as a direct smooth muscle relaxant and is frequently used as an antispasmodic in Irritable Bowel Syndrome (IBS). **3. NEET-PG High-Yield Pearls:** * **M1:** "Neural" (Gastric glands, CNS). * **M2:** "Cardiac" (SA node, AV node, Atria). * **M3:** "Glandular/Smooth Muscle" (Exocrine glands, Bronchi, Bladder, Eye). * **Mnemonic:** Remember **Q-I-Q** for G-protein linkage: M1 (Gq), M2 (Gi), M3 (Gq). * **Clinical Note:** Pilocarpine (M3 agonist) is used in glaucoma, while Atropine (Non-selective antagonist) is used to treat bradycardia by blocking M2 receptors.

Question 442: All of the following drugs may be used to relieve urinary spasms after urological procedures, EXCEPT:

A. Darifenacin
B. Oxybutynin
C. Tolterodine
D. Tiotropium (Correct Answer)

Explanation: The question tests your knowledge of the clinical applications of **Muscarinic Antagonists (Anticholinergics)**. **1. Why Tiotropium is the Correct Answer:** Tiotropium is a long-acting muscarinic antagonist (LAMA) specifically designed for **inhalation** [1]. It has high affinity for M3 receptors in the bronchial smooth muscle, leading to bronchodilation. Because it is administered via inhalation and has poor systemic absorption, it is used exclusively for **COPD and Asthma** [1]. It has no clinical role in treating urinary spasms. **2. Analysis of Incorrect Options (Drugs used for Urinary Spasms):** The bladder detrusor muscle is primarily contracted by **M3 receptors** [2]. To relieve urinary spasms or Overactive Bladder (OAB), we use M3-selective or non-selective muscarinic antagonists [2]: * **Oxybutynin:** A non-selective antagonist that also has direct spasmolytic effects [2]. It is a classic choice for post-surgical bladder spasms but has significant side effects (dry mouth, constipation). * **Tolterodine:** A potent antimuscarinic with relative functional selectivity for the bladder over salivary glands, making it better tolerated than oxybutynin [2]. * **Darifenacin:** A **highly selective M3 antagonist** [2]. By specifically targeting M3 receptors, it reduces detrusor contractions while minimizing M1/M2-mediated side effects (like tachycardia or cognitive impairment). **3. NEET-PG High-Yield Pearls:** * **M3 Selectivity:** Darifenacin and Solifenacin are the most M3-selective agents [2]. * **Mirabegron:** A **Beta-3 ($\beta_3$) agonist** is a newer alternative for OAB/urinary urgency, used when anticholinergics are contraindicated (e.g., in Glaucoma). * **Contraindication:** Avoid all these drugs in patients with **Narrow-Angle Glaucoma** and **Benign Prostatic Hyperplasia (BPH)** with significant obstruction.

Question 443: The metabolic effects of sympathomimetics are mediated by which receptors?

A. All beta-adrenergic receptors (Correct Answer)
B. Dopaminergic receptors
C. Beta 2 receptors
D. Opioid receptors

Explanation: **Explanation:** Sympathomimetics exert significant metabolic effects primarily through the activation of **beta-adrenergic receptors ($\beta_1, \beta_2,$ and $\beta_3$)**. While $\alpha$-receptors play a minor role (e.g., $\alpha_1$ can stimulate glycogenolysis), the predominant metabolic surge is mediated by the Beta-family via the Gs-protein/cAMP pathway. * **$\beta_1$ Receptors:** Primarily responsible for **renin release** from juxtaglomerular cells and contributing to lipolysis. * **$\beta_2$ Receptors:** Mediate **glycogenolysis** (liver and muscle) and **gluconeogenesis**, leading to increased blood glucose levels. They also stimulate insulin secretion and promote the uptake of potassium into skeletal muscles (hypokalemia). * **$\beta_3$ Receptors:** Located in adipose tissue, these are the chief mediators of **lipolysis** and thermogenesis. **Analysis of Incorrect Options:** * **Option B (Dopaminergic):** These receptors (D1-D5) are mainly involved in renal vasodilation and CNS modulation, not systemic metabolic regulation. * **Option C (Beta 2):** While $\beta_2$ is crucial for hyperglycemia, it is an incomplete answer because $\beta_1$ and $\beta_3$ are equally essential for the total metabolic profile (lipolysis and renin release). * **Option D (Opioid):** These are involved in analgesia and sedation, having no direct role in sympathomimetic metabolic pathways. **High-Yield NEET-PG Pearls:** * **Hypokalemia:** A classic side effect of $\beta_2$ agonists (like Salbutamol) due to the activation of the Na+/K+ ATPase pump. * **Diabetes Caution:** Non-selective beta-blockers (like Propranolol) can mask the tachycardia of hypoglycemia and delay recovery by inhibiting $\beta_2$-mediated glycogenolysis. * **$\beta_3$ Agonist:** **Mirabegron** is a clinical example used for overactive bladder, but it also stimulates lipolysis.

Question 444: Alprostadil is used for which of the following conditions?

A. Erectile dysfunction (Correct Answer)
B. Pulmonary hypertension
C. Patent ductus arteriosus (PDA)
D. Critical limb ischemia

Explanation: **Explanation:** **Alprostadil** is a synthetic analogue of **Prostaglandin E1 (PGE1)**. It acts as a potent vasodilator by increasing intracellular cAMP levels, leading to smooth muscle relaxation. **Why Option A is Correct:** In **Erectile Dysfunction (ED)**, Alprostadil is used as a second-line treatment (often when PDE-5 inhibitors like Sildenafil fail). It is administered via **intracavernosal injection** (Caverject) or **intraurethral suppository** (MUSE). It causes direct relaxation of the trabecular smooth muscle and dilation of cavernosal arteries, leading to an erection. **Analysis of Incorrect Options:** * **B. Pulmonary Hypertension:** While Prostaglandins are used here, the drug of choice is **Epoprostenol (PGI2)** or its analogues like Iloprost and Treprostinil, not Alprostadil. * **C. Patent Ductus Arteriosus (PDA):** This is a common distractor. Alprostadil is used to **maintain patency** of the ductus arteriosus in neonates with cyanotic heart disease (to keep it open). It is *not* used to treat/close a PDA; closure is achieved using NSAIDs like **Indomethacin** or Ibuprofen. * **D. Critical Limb Ischemia:** Although PGE1 has been trialed for peripheral vascular disease due to its vasodilatory properties, it is not the primary or standard FDA-approved indication compared to ED. **High-Yield Clinical Pearls for NEET-PG:** 1. **Misoprostol** is another PGE1 analogue used for peptic ulcer prevention (NSAID-induced) and medical abortion (combined with Mifepristone). 2. **Latanoprost** (PGF2α) is the drug of choice for Open-Angle Glaucoma. 3. **Dinoprostone** (PGE2) is used for cervical ripening and induction of labor. 4. **Side Effect:** The most common side effect of intracavernosal Alprostadil is penile pain and a risk of **priapism**.

Question 445: Which non-depolarizing neuromuscular blocking agent also acts as a ganglion blocker?

A. Atracurium
B. Pancuronium
C. D-tubocurarine (Correct Answer)
D. Gallamine

Explanation: **Explanation:** **D-tubocurarine** is the prototype of non-depolarizing (competitive) neuromuscular blockers. Its mechanism involves blocking nicotinic receptors at the motor endplate ($N_m$). However, it lacks absolute selectivity and also blocks nicotinic receptors at the autonomic ganglia ($N_n$). This **ganglionic blockade**, combined with significant **histamine release**, often leads to clinical hypotension and reflex tachycardia. **Analysis of Incorrect Options:** * **Atracurium:** Known for undergoing spontaneous degradation (**Hofmann elimination**). Its primary side effect is histamine release, but it does not cause significant ganglionic blockade. * **Pancuronium:** An aminosteroid compound that lacks ganglionic blocking activity. Instead, it exhibits **vagolytic** properties (blocks $M_2$ receptors in the heart), leading to tachycardia and hypertension. * **Gallamine:** Similar to pancuronium, it is primarily known for its strong **vagolytic effect** rather than ganglionic blockade. **High-Yield Clinical Pearls for NEET-PG:** * **Mivacurium:** The non-depolarizing blocker with the shortest duration of action; metabolized by plasma cholinesterase. * **Rocuranium:** The non-depolarizing agent with the fastest onset, making it an alternative for Rapid Sequence Induction (RSI). * **Sugammadex:** A specific reversal agent for aminosteroid blockers (Rocuranium > Vecuronium). * **Cisatracurium:** The isomer of atracurium that produces less laudanosine (a metabolite that can cause seizures), making it safer for prolonged infusions in the ICU.

Question 446: What is the major neurotransmitter released at the end-organ effectors of the sympathetic division of the autonomic nervous system?

A. Adrenaline
B. Noradrenaline (Correct Answer)
C. Dopamine
D. Acetylcholine

Explanation: **Explanation:** The autonomic nervous system (ANS) is divided into the sympathetic and parasympathetic divisions. The sympathetic nervous system typically follows a "two-neuron" chain: a short preganglionic fiber and a long postganglionic fiber. **Why Noradrenaline is correct:** In the sympathetic nervous system, **Noradrenaline (Norepinephrine)** is the primary neurotransmitter released by **postganglionic sympathetic nerve endings** onto end-organ effectors (alpha and beta receptors). It is synthesized from dopamine within the nerve terminals and is responsible for the "fight or flight" response in most organs, such as the heart and blood vessels. **Why the other options are incorrect:** * **Adrenaline:** While it is a major sympathetic hormone, it is primarily released into the bloodstream by the **adrenal medulla** (80% adrenaline, 20% noradrenaline) rather than at the direct nerve-effector junction. * **Dopamine:** This serves as a precursor to noradrenaline and acts as a neurotransmitter in specific areas like the basal ganglia and renal vasculature, but it is not the "major" neurotransmitter for general sympathetic effectors. * **Acetylcholine:** This is the neurotransmitter for **all preganglionic fibers** (both sympathetic and parasympathetic) and all postganglionic parasympathetic fibers. **High-Yield NEET-PG Pearls:** 1. **The Exception Rule:** Sweat glands are innervated by sympathetic nerves, but they release **Acetylcholine** (Sympathetic Cholinergic) instead of noradrenaline. 2. **Rate-limiting step:** The conversion of Tyrosine to DOPA by **Tyrosine Hydroxylase** is the rate-limiting step in noradrenaline synthesis. 3. **Termination of Action:** The primary mechanism for terminating the action of noradrenaline at the synapse is **uptake-1 (reuptake)** into the presynaptic terminal, not enzymatic degradation.

Question 447: Which drug blocks both H1 and 5-HT2 receptors?

A. Phenoxybenzamine
B. Cyproheptadine (Correct Answer)
C. Ritanserin
D. Ondansetron

Explanation: **Explanation:** The correct answer is **Cyproheptadine**. **Why Cyproheptadine is correct:** Cyproheptadine is a first-generation antihistamine with a unique pharmacological profile. It acts as a potent antagonist at both **H1 receptors** and **5-HT2 receptors**. Additionally, it possesses significant anticholinergic (muscarinic) and sedative properties. Because of its 5-HT2 blocking action, it is clinically used to manage **Serotonin Syndrome** and to stimulate appetite in children and cachectic patients. **Analysis of Incorrect Options:** * **Phenoxybenzamine:** This is primarily an irreversible, non-selective **alpha-blocker** (α1 and α2). While it does have some H1 and 5-HT blocking activity, it is clinically categorized and primarily tested as an alpha-adrenergic antagonist used in Pheochromocytoma. * **Ritanserin:** This is a selective **5-HT2 receptor antagonist**. It does not have significant H1 blocking activity. It has been studied for anxiety and sleep disorders but is not a dual H1/5-HT2 blocker like Cyproheptadine. * **Ondansetron:** This is a highly selective **5-HT3 receptor antagonist** used primarily as an anti-emetic (especially for chemotherapy-induced nausea). It has no action on H1 or 5-HT2 receptors. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** Cyproheptadine is the DOC for **Serotonin Syndrome** (though supportive care is first-line). * **Off-label use:** It is used to treat sexual dysfunction induced by SSRIs. * **Appetite Stimulation:** It causes weight gain by inhibiting the satiety center in the hypothalamus via 5-HT2 blockade. * **Dumping Syndrome:** It is also used in the management of post-gastrectomy dumping syndrome due to its anti-serotonergic effects.

Question 448: D-tubocurarine acts by?

A. Inhibiting nicotinic receptors at the myoneural junction (Correct Answer)
B. Inhibiting nicotinic receptors at the autonomic ganglion
C. Producing a depolarizing block
D. Inhibiting the reuptake of acetylcholine

Explanation: **Explanation:** **1. Why Option A is Correct:** D-tubocurarine is the prototype **competitive (non-depolarizing) neuromuscular blocker**. It acts by binding to the **nicotinic acetylcholine receptors ($N_M$ receptors)** located at the motor endplate of the myoneural (neuromuscular) junction. By acting as a competitive antagonist, it prevents acetylcholine from binding to these receptors, thereby preventing endplate potential and subsequent muscle contraction, leading to flaccid paralysis. **2. Why the Other Options are Incorrect:** * **Option B:** While D-tubocurarine can block nicotinic receptors at autonomic ganglia ($N_N$ receptors) at high doses (leading to hypotension), its primary therapeutic action and classification are based on its effect at the **myoneural junction**. * **Option C:** D-tubocurarine produces a **non-depolarizing block**. Depolarizing blocks are characteristic of drugs like **Succinylcholine**, which act as agonists that cause persistent depolarization. * **Option D:** Inhibiting the reuptake of acetylcholine is not a mechanism of muscle relaxants. Acetylcholine is primarily inactivated by enzymatic degradation (Acetylcholinesterase), not reuptake. **3. NEET-PG High-Yield Pearls:** * **Reversibility:** The block produced by D-tubocurarine can be reversed by **Acetylcholinesterase inhibitors** (e.g., Neostigmine), which increase ACh levels to outcompete the drug. * **Side Effects:** A classic side effect of D-tubocurarine is **histamine release**, which can cause bronchospasm and hypotension. * **Order of Paralysis:** Small, rapidly moving muscles (eyes, fingers) are paralyzed first; the **diaphragm** is the last to be paralyzed and the first to recover. * **Modern Alternative:** In clinical practice, D-tubocurarine is largely replaced by agents like **Atracurium** (safe in renal failure due to Hofmann elimination) or **Rocuranium**.

Question 449: Which of the following parasympathomimetic drugs is used to treat xerostomia?

A. Bethanechol
B. Cevimeline (Correct Answer)
C. Tolterodine
D. Pirenzepine

Explanation: **Explanation:** **Cevimeline** is a synthetic muscarinic agonist with a high affinity for **M3 receptors** located on salivary and lacrimal glands. By stimulating these receptors, it increases secretions, making it a first-line treatment for **xerostomia** (dry mouth), particularly in patients with **Sjögren’s syndrome** or those undergoing head and neck radiation. **Analysis of Options:** * **Bethanechol (A):** While it is a choline ester, it acts preferentially on **M3 receptors in the bladder and GI tract**. It is clinically used to treat post-operative urinary retention and paralytic ileus, not xerostomia. * **Tolterodine (C):** This is a **muscarinic antagonist** (anticholinergic) used to treat overactive bladder. A common side effect of this drug is actually causing xerostomia, not treating it. * **Pirenzepine (D):** This is a selective **M1 receptor antagonist** formerly used to reduce gastric acid secretion in peptic ulcer disease. Being an antagonist, it would decrease rather than increase secretions. **High-Yield NEET-PG Pearls:** * **Pilocarpine** is the other major sialagogue (saliva inducer) used for xerostomia and is also used topically for glaucoma (miotic). * **Sjögren’s Syndrome Triad:** Dry eyes (xerophthalmia), dry mouth (xerostomia), and rheumatoid arthritis. * **Contraindications:** Parasympathomimetics like Cevimeline should be used cautiously in patients with **asthma or COPD** (due to bronchoconstriction) and **acute iritis**.

Question 450: A 28-year-old woman has been treated with several autonomic drugs for about a month. Which of the following signs would distinguish between an overdose of a muscarinic blocker and a ganglionic blocker?

A. Blurred vision
B. Dry mouth, constipation
C. Mydriasis
D. Postural hypotension (Correct Answer)

Explanation: **Explanation:** To distinguish between a muscarinic blocker (e.g., Atropine) and a ganglionic blocker (e.g., Hexamethonium or Mecamylamine), one must identify the site of action. Muscarinic blockers only affect the parasympathetic neuroeffector junction, while ganglionic blockers interrupt **both** sympathetic and parasympathetic transmission at the autonomic ganglia. **1. Why Postural Hypotension is the Correct Answer:** Blood pressure is primarily maintained by the sympathetic nervous system's control over vascular tone (via $\alpha_1$ receptors). * **Muscarinic blockers** have no effect on blood vessels (as most vessels lack parasympathetic innervation) and thus do not cause significant postural hypotension. * **Ganglionic blockers** inhibit the sympathetic outflow to the vasculature, leading to profound vasodilation and a failure of the baroreceptor reflex. This results in severe **postural (orthostatic) hypotension**, making it the hallmark distinguishing feature. **2. Why Other Options are Incorrect:** * **A, B, and C (Blurred vision, Dry mouth, Mydriasis):** These are signs of **parasympathetic blockade**. Since the parasympathetic system is the "dominant tone" for the eye (pupil and ciliary muscle), salivary glands, and GI tract, both muscarinic blockers and ganglionic blockers will produce these symptoms. Therefore, they cannot be used to differentiate between the two. **NEET-PG High-Yield Pearls:** * **Dominant Tone Rule:** To predict ganglionic blocker effects, remember the dominant tone of the organ. If the dominant tone is parasympathetic (Heart, Eye, GI, Bladder), blocking the ganglion looks like an atropine-like effect. If the dominant tone is sympathetic (Arterioles, Veins, Sweat glands), it looks like a sympathetic blockade. * **Exception:** Sweat glands are anatomically sympathetic but neurochemically cholinergic. Ganglionic blockers decrease sweating, whereas muscarinic blockers also decrease sweating (except for stress-induced sweating).

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free